346 related articles for article (PubMed ID: 34876060)
21. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Rudin CM; Awad MM; Navarro A; Gottfried M; Peters S; Csőszi T; Cheema PK; Rodriguez-Abreu D; Wollner M; Yang JC; Mazieres J; Orlandi FJ; Luft A; Gümüş M; Kato T; Kalemkerian GP; Luo Y; Ebiana V; Pietanza MC; Kim HR;
J Clin Oncol; 2020 Jul; 38(21):2369-2379. PubMed ID: 32468956
[TBL] [Abstract][Full Text] [Related]
23. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.
Owonikoko TK; Dahlberg SE; Sica GL; Wagner LI; Wade JL; Srkalovic G; Lash BW; Leach JW; Leal TB; Aggarwal C; Ramalingam SS
J Clin Oncol; 2019 Jan; 37(3):222-229. PubMed ID: 30523756
[TBL] [Abstract][Full Text] [Related]
24. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study.
Skarlos DV; Samantas E; Kosmidis P; Fountzilas G; Angelidou M; Palamidas P; Mylonakis N; Provata A; Papadakis E; Klouvas G
Ann Oncol; 1994 Sep; 5(7):601-7. PubMed ID: 7993835
[TBL] [Abstract][Full Text] [Related]
25. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang L; Huang R; Chu Z; Zhan Q
J Thorac Oncol; 2010 Jun; 5(6):867-73. PubMed ID: 20521354
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Yoshimura A; Noro R; Miyanaga A; Mizutani H; Kosaihira S; Minegishi Y; Seike M; Hino M; Ando M; Nomura K; Okano T; Kobayashi K; Gemma A;
Anticancer Res; 2012 Oct; 32(10):4473-8. PubMed ID: 23060575
[TBL] [Abstract][Full Text] [Related]
28. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
Byers LA; Bentsion D; Gans S; Penkov K; Son C; Sibille A; Owonikoko TK; Groen HJM; Gay CM; Fujimoto J; de Groot P; Dunbar M; Kang K; He L; Sehgal V; Glasgow J; Bach BA; Ellis PM
Clin Cancer Res; 2021 Jul; 27(14):3884-3895. PubMed ID: 33947690
[TBL] [Abstract][Full Text] [Related]
29. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
30. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
Sun Y; Cheng Y; Hao X; Wang J; Hu C; Han B; Liu X; Zhang L; Wan H; Xia Z; Liu Y; Li W; Hou M; Zhang H; Xiu Q; Zhu Y; Feng J; Qin S; Luo X
BMC Cancer; 2016 Apr; 16():265. PubMed ID: 27061082
[TBL] [Abstract][Full Text] [Related]
32. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
Hermes A; Bergman B; Bremnes R; Ek L; Fluge S; Sederholm C; Sundstrøm S; Thaning L; Vilsvik J; Aasebø U; Sörenson S
J Clin Oncol; 2008 Sep; 26(26):4261-7. PubMed ID: 18779613
[TBL] [Abstract][Full Text] [Related]
33. A comparative study on etoposide combined with lobaplatin or cisplatin in the first-line treatment of extensive-stage small cell lung cancer.
Li S; Liang Y; Wu Y; Huang Z; Lin Y; Yang Z; Chen H; Wu A
J BUON; 2020; 25(3):1490-1496. PubMed ID: 32862595
[TBL] [Abstract][Full Text] [Related]
34. Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study.
Luo J; Wu FY; Li AW; Zheng D; Liu JM
Asian Pac J Cancer Prev; 2012; 13(9):4703-6. PubMed ID: 23167406
[TBL] [Abstract][Full Text] [Related]
35. Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Han D; Wang G; Sun L; Ren X; Shang W; Xu L; Li S
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28707433
[TBL] [Abstract][Full Text] [Related]
36. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
Jiang L; Yang KH; Guan QL; Mi DH; Wang J
Intern Med J; 2012 Dec; 42(12):1297-309. PubMed ID: 22530708
[TBL] [Abstract][Full Text] [Related]
38. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Salgia R; Stille JR; Weaver RW; McCleod M; Hamid O; Polzer J; Roberson S; Flynt A; Spigel DR
Lung Cancer; 2017 Mar; 105():7-13. PubMed ID: 28236984
[TBL] [Abstract][Full Text] [Related]
39. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Lara PN; Natale R; Crowley J; Lenz HJ; Redman MW; Carleton JE; Jett J; Langer CJ; Kuebler JP; Dakhil SR; Chansky K; Gandara DR
J Clin Oncol; 2009 May; 27(15):2530-5. PubMed ID: 19349543
[TBL] [Abstract][Full Text] [Related]
40. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
